Help Your Patients Carry on with Confidence with VALTOCO® (diazepam nasal spray)
Join us for an insightful 45-minute session with our panel to:
-
Understand the impact that episodes of frequent seizures can have on the lives of people with epilepsy (PWE)
-
Discuss the importance of Seizure Action Plans in the lives of PWE
-
Explore the role of immediate-use seizure (rescue) medications in the management of episodes of frequent seizures
*Individual results may vary
Indication
VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.
Register Below
Speaker
Biography
Speaker
Nancy Santilli, PNP, MN, FAAN
General Manager
Human Care Systems
Sunnyvale, CA
Biography
Ms. Nancy Santilli has served as the Global Managing Director of Human Care Systems, Inc., since 2014. Prior, she worked at Endo Health Solutions (Chadds Ford, PA), Elan Pharmaceuticals (Dublin, Ireland), and the University of Virginia School of Medicine (Charlottesville, VA) where she was the Associated Director of the Comprehensive Epilepsy Program and Associate Professor of Neurology, School of Medicine.
Ms. Santilli earned her MSN degree and NP certification from the University of Virginia in Charlottesville, and she received her BSN from Seton Hall University in South Orange, NJ.
Ms. Santilli has held numerous leadership positions. She is the Chair Emeritus of the Healthcare Businesswomen’s Association, Past President of the Epilepsy Foundation, and Past Treasurer of the American Epilepsy Society. She secured and led multiple clinical trials evaluating new therapies for epilepsy. She is well published, having authored 37 articles and chapters, 50 abstracts, and two books. She is a Fellow of the American Academy of Nursing and a recipient of the International League Against Epilepsy Ambassador Award.
Speaker
Biography
Speaker
Brittani Ireland, DNP
Patient Services Manager; Pediatric Nurse Practitioner
Neurelis, Inc.
Memphis, TN
Biography
Brittani has over 14 years of experience in caring for patients with epilepsy. She began her career as a nurse at Le Bonheur Children’s Hospital, a Level 4 Comprehensive Epilepsy Center. She earned her Doctor of Nursing Practice and became a certified pediatric nurse practitioner in 2016. She has most recently worked as a nurse practitioner at Le Bonheur Children’s Hospital in the neurology clinic and with the neurology inpatient team for almost 6 years.
Brittani’s work as a nurse and nurse practitioner has given her an understanding of how to advocate for patients and families affected by epilepsy. Navigating the challenges of the “epilepsy world” can be overwhelming, and Brittani is passionate about alleviating that stress and making a meaningful impact in the lives of patients and their families.
Speaker
Speaker
Danielle L
Patient Ambassador with episodes of frequent seizures
Speaker
Speaker
Esteban G
Patient Ambassador with episodes of frequent seizures
Help Your Patients Carry on with Confidence with VALTOCO® (diazepam nasal spray)
Indication
NEURELIS, VALTOCO, and the NEURELIS and VALTOCO logos are trademarks of Neurelis, Inc.
US-PRC-25-00262-v1 11/2025
VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.
IMPORTANT SAFETY INFORMATION
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
- The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.
- The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.
Contraindications: VALTOCO is contraindicated in patients with:
- Hypersensitivity to diazepam
- Acute narrow-angle glaucoma
Central Nervous System (CNS) Depression
Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.
The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.
Suicidal Behavior and Ideation
Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.
Glaucoma
Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.
Neonatal Sedation and Withdrawal Syndrome
Use of VALTOCO late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to VALTOCO during pregnancy or labor for signs of sedation and monitor neonates exposed to VALTOCO during pregnancy for signs of withdrawal; manage these neonates accordingly.
Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative
VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome,” can occur in neonates and low-birth-weight infants treated with benzyl alcohol–preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.
Adverse Reactions
The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.
Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.
To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).
Please read full Prescribing Information, including Boxed Warning, for additional important safety information.
© Neurelis, Inc. 2025. All rights reserved.NEURELIS, VALTOCO, and the NEURELIS and VALTOCO logos are trademarks of Neurelis, Inc.
US-PRC-25-00262-v1 11/2025